Soleno Therapeutics
A clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
The company’s lead candidate, DCCR (Diazoxide Choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome, completed its Phase III development program to support a planned New Drug Application submission in 2023.
Latest Soleno Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze